Highlights EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Real-time Estimate Cboe BZX Other stock markets 03:54:07 2024-04-29 pm EDT			5-day change	1st Jan Change
17.62 ^USD	+5.22%		+5.01%	-22.98%

Apr. 02	EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	CI
Mar. 18	EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	Mar. 07	MT
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M	Mar. 07	MT
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	Feb. 03	CI
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals	Jan. 17	MT
EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema	Jan. 10	CI
EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints	Dec. 04	CI
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q3 Revenue $15.2M, vs. Street Est of $7.4M	Nov. 01	MT
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023	23-09-11	CI
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Reports Q2 Revenue $9.1M, vs. Street Est of $42.1M	23-08-02	MT
EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901	23-07-27	CI
Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy	23-06-05	CI
EyePoint Sells Yutiq Rights to Alimera Sciences for $82.5 Million	23-05-18	MT
Eyepoint Pharmaceuticals, Inc. Enters into A Product Rights Agreement with Alimera Sciences, Inc	23-05-18	CI
Alimera Sciences, Inc. acquired YUTIQÂ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.	23-05-17	CI
Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.	23-05-17	CI
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $7.7M, vs. Street Est of $7.6M	23-05-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Highlights

Filters